Advanced Search

    Technical Analysis for ALVR - AlloVir, Inc.

    Grade Last Price % Change Price Change
    D 6.04 -5.63% -0.36
    ALVR closed down 5.63 percent on Wednesday, February 8, 2023, on 73 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Down
    Historical ALVR trend table...
    Date Alert Name Type % Chg
    Fell Below 200 DMA Bearish 0.00%
    Earnings Movers Other 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Bearish Engulfing Bearish -5.63%
    Upper Bollinger Band Walk Strength -5.63%
    Wide Bands Range Expansion -5.63%
    Overbought Stochastic Strength -5.63%
    Down 3 Days in a Row Weakness -5.63%
    Older End-of-Day Signals for ALVR ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    Down 5% about 9 hours ago
    Fell Below 10 DMA about 9 hours ago
    10 DMA Support about 10 hours ago
    200 DMA Support about 10 hours ago
    Fell Below 200 DMA about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators Basic chart:

    Profile

    AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biology Immune System Stem Cell Gene Therapy Cell Biology Cell Therapy Manufacturing Process Proprietary Technology Viruses Viral Disease Virus Immunity Zoonoses Shimon Slavin Covid 19

    Is ALVR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Feb 7 Sage and Biogen's NDA for Depression Drug Gets Priority Review
    Feb 1 AlloVir to Participate in the SVB Securities Global Biopharma Conference
    Jan 25 How Much Upside is Left in AlloVir, Inc. (ALVR)? Wall Street Analysts Think 355.8%
    Jan 25 Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
    Jan 9 AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
    Jan 3 AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
    Dec 10 AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition
    Nov 15 AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
    Nov 10 AlloVir: Solid Data, But Market Isn't Paying Attention
    Nov 3 AlloVir GAAP EPS of -$0.50 beats by $0.03
    See more ALVR news...

    Indicators

    Indicator Value
    52 Week High 10.29
    52 Week Low 3.17
    Average Volume 230,875
    200-Day Moving Average 6.19
    50-Day Moving Average 6.00
    20-Day Moving Average 5.78
    10-Day Moving Average 6.12
    Average True Range 0.42
    RSI 52.15
    ADX 20.55
    +DI 28.14
    -DI 17.43
    Chandelier Exit (Long, 3 ATRs) 5.70
    Chandelier Exit (Short, 3 ATRs) 6.21
    Upper Bollinger Bands 6.69
    Lower Bollinger Band 4.88
    Percent B (%b) 0.64
    BandWidth 31.15
    MACD Line 0.14
    MACD Signal Line 0.03
    MACD Histogram 0.1097
    Fundamentals Value
    Market Cap 372.42 Million
    Num Shares 61.7 Million
    EPS
    Price-to-Sales 0.00
    Price-to-Book 7.27
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 6.61
    Resistance 3 (R3) 6.67 6.55 6.52
    Resistance 2 (R2) 6.55 6.40 6.52 6.48
    Resistance 1 (R1) 6.29 6.31 6.23 6.23 6.45
    Pivot Point 6.17 6.17 6.14 6.14 6.17
    Support 1 (S1) 5.91 6.02 5.85 5.85 5.63
    Support 2 (S2) 5.79 5.93 5.76 5.60
    Support 3 (S3) 5.53 5.79 5.57
    Support 4 (S4) 5.47